ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2409

Do Children with Juvenile Idiopathic Arthritis Play an Active Role in Their Treatment Adherence? First Results of the Rumaji Study

Guillaume Montagu1, Ellie Mevel1, William FAHY2, Linda Rossi-Semerano3, Elisabeth Solau-Gervais4, Sonia Tropé5 and Jean-David Cohen6, 1Research, Unknowns, strategy and innovation consulting, PARIS, France, 2KOURIR, Paris, France, 3Paediatric Rheumatology, Hôpital Kremlin Bicêtre, PARIS, France, 4Service de Rhumatologie, CHRU de Poitiers, Poitiers, France, 5149 avenue du Maine, ANDAR, Paris, France, 6IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Compliance, juvenile idiopathic arthritis (JIA), qualitative, skill development and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Title: Pediatric Rheumatology – Clinical Poster II – ARHP

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Adherence to DMARDs such as methotrexate and biologics is critical for patients with Juvenile Idiopathic Arthritis (JIA). Notwithstanding, few studies exists on that topic and we lack information to understand the grounds for adherence.

The RUMAJI study aims, among others, to understand and decipher the parents and children adherence mechanisms and practices.

Methods: Qualitative methods were chosen in order to investigate parents’ and children’s everyday life with JIA and its treatment. An ethnographic study was designed by a multidisciplinary team including rheumatologists, pediatricians, patient associations members and anthropologists. Parents, children and doctors were interviewed. The study involved 6 doctors (3 paediatricians and 3 rheumatologists) and 15 families (enough to reach saturation), recruited from 5 centers, by diversity of clinical and sociological profiles. The panel included 17 children with JIA, 11 girls and 6 boys, median age 10 [3 ; 17], median disease duration 2.5 [1 ; 15]. 4 children were treated with conventional DMARDs in monotherapy, 4 with biologic DMARDs in monotherapy, 5 with cDMARDbDMARD association and 4 with NSAIDs only.

Doctors interviews were conducted first. Parents and children interviews were conducted by anthropologists at family’s home using indepth semi directive and biographic methods. 3 fields were explored: organization of everyday life with JIA, treatment practices, impact on school and social activities. Interviews were recorded and transcribed for analysis.

Results: Adherence results from an appropriation process of the JIA and treatment that require both an active role from parents and children, even before the transition. The setting of a partnership-based doctor-children-and-parents relationship has also a positive effect in the family active role. The active role played by children could be either stimulated or inhibited at home according to the family’s structure, social background, parents’ attitudes toward their child (participation to the decision, explanation of the disease). Children’s active role includes in particular: 1) negotiations with parents and physicians, 2) experiments with the treatment (forgetting or involuntary switch from the parents, changing the dosage on their own initiative) and 3) participation to the treatment administration and ritualization.

The manner children consider and manage their DMARDs is the result of an arbitration depending on the positive (a) and side effects (b) they felt in their body and the effects noted by the doctors (c) during the examinations and test results. Dealing with these 3 dimensions requires to link together both a theoretical and practical knowledge of JIA. Thus, children build their own and singular knowledge of their disease and treatment, which is a source of control of their body and their life.

Conclusion: Qualitative methods, through an ethnographic study starting from children, parents and doctors point of view, underline the active role they played by children in their care. Adherence to DMARDs could be improved by supporting children’s implication as soon as the beginning of JIA.


Disclosure: G. Montagu, None; E. Mevel, None; W. FAHY, None; L. Rossi-Semerano, None; E. Solau-Gervais, AbbVie Inc., 8,Merck & Co., 8,Celgene Corporation, 8,Novartis, 8; S. Tropé, Nordic Pharma, 6; J. D. Cohen, None.

To cite this abstract in AMA style:

Montagu G, Mevel E, FAHY W, Rossi-Semerano L, Solau-Gervais E, Tropé S, Cohen JD. Do Children with Juvenile Idiopathic Arthritis Play an Active Role in Their Treatment Adherence? First Results of the Rumaji Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/do-children-with-juvenile-idiopathic-arthritis-play-an-active-role-in-their-treatment-adherence-first-results-of-the-rumaji-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-children-with-juvenile-idiopathic-arthritis-play-an-active-role-in-their-treatment-adherence-first-results-of-the-rumaji-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology